Search Results
Nov 04, 2025, 12:00 ET RO TO PRESENT EIGHT RESEARCH ABSTRACTS AT OBESITYWEEK 2025
least four weeks of treatment with a branded GLP-1 through Ro's platform. A majority of patients who responded to the survey reported improvements across multiple joint and mobility measures. The findings suggest that GLP-1 treatment may alleviate OA symptoms and improve quality
More news about: Ro
Nov 04, 2025, 10:00 ET Hohenstein Medical Hires Medical Device Testing Expert Katie Brinkman to Lead Biocompatibility Program
Hohenstein.US/Medical About Hohenstein MedicalHohenstein Medical is a global, best-in-class GLP-certified and ISO/IEC 17025-accredited laboratory, conducting biocompatibility testing for medical devices, including chemical screenings, biological
More news about: Hohenstein Medical
Nov 04, 2025, 09:02 ET Phenomix Sciences Expands Evidence for MyPhenome™ Test Predicting GLP-1 Response and Obesity Risk in Large, Diverse Populations
Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery patients.
More news about: Phenomix Sciences
Nov 04, 2025, 08:00 ET DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025
highlighted by an oral presentation from Dr. Steven Brunelli titled "GLP-1 Receptor Agonist Use Associated with Improvement in Hospitalization Rates in Patients with ESKD." This study, which explores how GLP-1 receptor agonists may reduce hospitalizations among patients with end-stage
More news about: DaVita
Nov 04, 2025, 08:00 ET Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
and android fat) and beneficial liver and bone health effects. As adjunct therapy to incretin mimetics, LPCN 2401 has potential to amplify GLP-1 action, ameliorate loss of muscle mass, improve muscle quality and functionality, and amplify fat mass loss with improved body composition, with
More news about: Lipocine Inc.
Nov 03, 2025, 16:00 ET Physician and New York Times Best-Selling Author Dr. Michael Greger Offers CMEs
Dr. Greger's recorded CME-approved webinars can be completed on demand, and topics include osteoporosis, GLP-1 pharmaceuticals, hair loss, and lowering LDL cholesterol. Physicians are able to receive one to three credits for each webinar.
More news about: NutritionFacts
Nov 03, 2025, 08:30 ET Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
absorbed. The new site will also be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist. The company expects to submit orforglipron to global regulatory agencies for obesity by the end of this year.
More news about: Eli Lilly and Company
Nov 03, 2025, 08:00 ET Orforgliprona, GLP-1 oral da Lilly, demonstra controle glicêmico superior em dois estudos bem-sucedidos de Fase 3, reconfirmando seu potencial como opção de tratamento do diabetes tipo 2
Sobre a orforglipronaA orforgliprona é uma molécula sintética (não peptídica) agonista do receptor do peptídeo semelhante ao glucagon-1 (GLP-1) oral, experimental, de dose única diária, que pode ser tomada a qualquer hora do dia sem restrições de ingestão de alimentos e água.4 A
More news about: Eli Lilly do Brasil
Nov 03, 2025, 03:47 ET 諾和諾德於香港推出體重管理藥物維秀美® （Wegovy®）
亦是香港首款獲批使用於12歲及以上青少年體重管理的每週一次處方減重藥物。 維秀美® 的活性成分司美格魯肽（Semaglutide），屬於胰高糖素樣肽-1（GLP-1）受體促效劑，能有效調節食慾。透過調節大腦中樞控制飢餓與飽腹感的區域，維秀美® 可助患者降低能量攝取、增強飽腹感、控制過度進食，並減低食慾出現的頻率及強度。 作為全球首款每週一次、專為長期體重管理而設的GLP-1受體促效劑，維秀美
More news about: 諾和諾德
Nov 01, 2025, 09:00 ET NOVAK DJOKOVIC LAUNCHES COB FOODS - SORGHUM-BASED SNACKS - AS CO-FOUNDER AND LEAD INVESTOR
crops in the U.S. Sorghum, by contrast, is a true superfood and nutritional powerhouse. It is a resistant starch, which can naturally boost your body's GLP-1s to keep you fuller longer, and it is also packed with antioxidant polyphenols and prebiotic fibre, which is great for gut health. It's also as good
More news about: Cob Foods
Oct 30, 2025, 16:54 ET BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M
solutions can address specific needs or gaps, making the Company an attractive 'go-to' partner for targeted immunotherapies; (2) identifying remaining GLP supply or production of (non-GMP) preclinical supply of DPX to be used in conducting research, preclinical supply of DPX+peanut antigen for the peanut
More news about: BioVaxys Technology Corp.
Oct 30, 2025, 12:41 ET Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®
2025. The new data highlight and underscore the differentiated profile of CONTRAVE® (naltrexone HCl/bupropion HCl) as an oral, non-GLP-1, combination therapy that helps adults manage weight by reducing appetite and supporting sustainable, long-term outcomes.
More news about: Currax Pharmaceuticals LLC
Oct 30, 2025, 12:00 ET ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
CMC process research and scale-up for API (Active Pharmaceutical Ingredient) and DP (Drug Product) manufacturing supporting non-GLP and GLP studies, Medicinal chemistry support for backup series development,
More news about: ChemDiv
Oct 30, 2025, 11:00 ET Doctor Creates the First Ever Healthy Energy Drink
Elixir's science-driven formula features allulose, a plant-based sweetener shown in studies to activate GLP-1 and suppress appetite; the same pathway targeted by today's leading weight-loss medications. One early tester said,
More news about: Elixir
Oct 30, 2025, 10:35 ET Cardiovascular, Renal & Metabolic (CRM) Diseases Market to Reach USD 451.87 Billion by 2033, Driven by Rising Burden of Chronic Conditions | DataM Intelligence
Advances in therapies: Industry players are increasingly deploying combination treatments (e.g., SGLT-2 inhibitors, GLP-1 receptor agonists) that address multiple disease axes, enhancing patient outcomes and expanding market size. Expanding
More news about: DataM Intelligence 4 Market Research LLP
Oct 30, 2025, 10:18 ET Competitive Landscape of Obesity Therapeutics Market Enters High-Growth Phase, Fueled by GLP-1 Surge and Expanding Oral Treatments | DataM Intelligence
operating alongside dominant GLP-1 companies and emerging biotechs focused on next-gen mechanisms. From a quantitative perspective: The GLP-1 class alone is expected to generate
More news about: DataM Intelligence 4 Market Research LLP
Oct 30, 2025, 09:00 ET GNC Publishes Groundbreaking GLP-1 Supplement Review to Guide Clinicians to Support GLP-1 Consumers
As GLP-1 medications such as Ozempic and Wegovy continue to reshape how consumers and clinicians approach weight loss, this review addresses a critical knowledge gap: how dietary supplements can complement GLP-1 therapy to support muscle health, nutrition,
More news about: GNC
Oct 30, 2025, 09:00 ET eMed Partners With Thrive Global to Deliver an Integrated End-to-End Obesity Care Program
integrated, digital-first clinical platform for GLP-1 and GIP medication management and combines it with Thrive Global's behavior change and lifestyle technology to deliver a truly comprehensive solution. "Access to affordable GLP-1s is just the start. Our partnership fuses
More news about: eMed
Oct 30, 2025, 08:00 ET ChemDiv's Discovery Platform Enables Differentiated, Reversible Pan‑EGFR Kinase Inhibitors for GFR‑Mutant Lung Cancer
methods (purity, potency, related substances); and Pre‑formulation to enable non‑GLP and GLP toxicology material supply. These activities are designed to support pre‑IND readiness while
More news about: ChemDiv
Oct 30, 2025, 08:00 ET Pilatus Biosciences to Present New Preclinical Data Highlighting PLT012's Ability to Induce Durable Anti-Tumor Immunity Through Immunometabolic Reprogramming of the Tumor Microenvironment at SITC 2025 Annual Meeting
immune memory that sustains tumor control and protects against rechallenge." Dr. Raven Lin, CEO of Pilatus Biosciences, added "Alongside a favorable GLP toxicology profile, these data support our planned Phase I study, with first patient in (FPI) targeted for Q1 2026." Details
More news about: Pilatus Biosciences
Oct 30, 2025, 06:45 ET Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type
More news about: Eli Lilly and Company
Oct 29, 2025, 20:10 ET Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
excellent chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation with other peptides including ASC35, a GLP-1R/GIPR dual agonist. -Submission of an Investigational New Drug Application (IND) for ASC36 to the
More news about: Ascletis Pharma Inc.
Oct 29, 2025, 20:10 ET 歌禮選定同類最佳每月一次皮下注射胰澱素受體激動劑ASC36進入臨床開發階段
ASC36單藥正在開發中，作為治療包括肥胖症在內的心髒代謝疾病的基石療法（cornerstone therapy），同時，基於ASC36的聯合療法也正在開發中。歌禮計劃將ASC36（胰澱素受體激動劑）和每月皮下給藥一次的ASC35（GLP-1R/GIPR雙靶點激動劑）聯用，治療肥胖症。 歌禮的AISBDD與ULAP技術可設計、優化並開發多款每月一次皮下注射超長效多肽，包括ASC35和ASC36。基於多肽的特性，本公司可利用其專有的ULAP技術，為皮下儲庫中的多肽設計多種緩釋速率常數（k），從而在預設的給藥間隔內精確釋放注射的多肽，降低血藥濃度峰谷比並改善臨床療效。
More news about: 歌禮製藥有限公司
Oct 29, 2025, 16:05 ET Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025
Central Time About GLP-1 and Dual GLP-1/GIP Agonists Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body
More news about: Viking Therapeutics, Inc.
Oct 29, 2025, 16:01 ET Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
A clinical study of tradipitant in the prevention of vomiting induced by a GLP-1 analog, Wegovy® (semaglutide), is now complete. Results are expected in the fourth quarter of 2025. On October
More news about: Vanda Pharmaceuticals Inc.